A new peer-reviewed study has found that nearly nine in 10 Americans view supervised psilocybin use as morally acceptable — a striking sign of how quickly public opinion on psychedelic-assisted therapy has shifted. The finding crosses political lines in ways that few issues do today.
At a glance
- Bipartisan support: 91% of liberals and 86% of conservatives said they approve of supervised psilocybin use for treating psychiatric conditions.
- Well-being enhancement: Support for using psilocybin to promote well-being in healthy individuals was nearly as high — 89% of liberals and 78% of conservatives approved.
- Study scope: Researchers surveyed 795 demographically representative U.S. adults, publishing their findings in the American Journal of Bioethics Neuroscience.
What the study found
The research team — drawing from institutions including the universities of Oxford, Yale, Johns Hopkins, and Granada — asked participants to imagine a future in which a supervised psilocybin law, modeled on Oregon’s existing framework, had been enacted at the federal level. Participants were given accurate information about psilocybin’s safety profile and its status as a non-addictive substance when used in controlled settings.
They were then asked to rate the moral acceptability of a fictional individual using psilocybin under professional supervision — either to treat a mental health condition or to enhance their overall well-being. In both cases, participants rated the decision as morally positive.
“Our results revealed strong bipartisan support for supervised psilocybin use for either treatment (89%) or enhancement (85%) in a demographically representative sample of US Americans,” the authors wrote.
The survey was conducted in the summer of 2021 C.E., before several additional states moved toward psilocybin reform — which means current support may well be higher.
Why it matters for policy
Public attitudes rarely make headlines in medical research. But for a substance that remains federally classified as a Schedule I drug in the U.S., understanding what the public actually thinks is important for anyone hoping to change the law.
The authors argued their findings have direct policy implications: “Given such bipartisan positive attitudes, future legislative changes allowing psychedelic use in supervised settings for both purposes, even at the federal level, seem unlikely to trigger major public backlash.”
That matters because the legislative landscape has been moving fast. States including Oregon and Colorado have already legalized supervised psilocybin services. Lawmakers in New York, Vermont, Arizona, California, Hawaii, and more than a dozen other states have introduced or advanced related bills. A Missouri House committee unanimously approved a bill to allow medical use by veterans. The momentum is real.
The study also found an interesting driver of support: people’s “care values” — a measure of how much they prioritize compassion and concern for others — were associated with moral approval of psilocybin use. The authors suggested this partly explains why liberals showed slightly higher support, since they tend to score higher on care-based moral reasoning. Age was a factor too: younger adults were more supportive than older ones, though majorities across age groups still approved.
The science behind the shift
Public attitudes don’t shift in a vacuum. Over the past decade, a wave of clinical research has made psilocybin one of the most studied psychedelic compounds in history. Johns Hopkins researchers have published promising results for treatment-resistant depression, addiction, and end-of-life anxiety. The U.S. National Institute of Mental Health has funded studies exploring its mechanisms. The FDA has granted psilocybin “Breakthrough Therapy” designation for major depressive disorder — twice.
A separate Canadian study found that 79.3% of adults consider psilocybin-assisted therapy a reasonable medical choice for people facing end-of-life existential distress, and 84.8% said the public health system should cover the costs. These findings suggest the American shift is part of a broader international rethinking of how societies approach mental health treatment.
Reason for hope — and caution
The study’s authors are careful not to overreach. They warn against what they call “the apparent hype bubble now surrounding the so-called ‘psychedelic Renaissance.'” One phase II clinical trial found no significant difference in primary endpoints between psilocybin and the antidepressant escitalopram for major depressive disorder — a reminder that psilocybin is not a universal solution.
“Psilocybin is not a silver bullet for treating mental illness,” the authors write. The research field is still young, and both overstating and understating trial results has been a documented problem.
What the study does offer is a clearer picture of where the public stands — and the picture is more unified than almost any other issue in American life right now. That kind of consensus is rare. Whether policymakers choose to act on it is another question entirely.
“If the field can overcome scientific inaccuracies, pursue rigorous research, and build trust,” the authors conclude, “then psychedelics such as psilocybin may one day be seen as a mainstream means to treat mental illness and possibly also to promote overall well-being.”
Read more
For more on this story, see: DoubleBlind Magazine
For more from Good News for Humankind, see:
- Renewables now make up at least 49% of global power capacity
- U.K. cancer death rates down to their lowest level on record
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
